text_1: 在 纳武利 尤 单抗 + 伊匹 单抗 组和 化疗 组中 , 研究者 认为 与 试验 相关 的 3 级 或 4 级 不良 事件 的 发生率 相似 ( 32.8% vs . 36.0% ) .
  
text_2: the frequency of grade 3 or 4 adverse events that were determined by the investigator to be related to the trial treatment was similar in the group that received nivolumab plus ipilimumab and in the chemotherapy group ( 32.8 % vs. 36.0 % ) .
  